An upcoming article in the September issue of the journal Critical Reviews in Oncology/Hematology addresses issues related to the maintenance of sexual function for men with prostate cancer on androgen deprivation therapy (ADT). … READ MORE
Filed under: Uncategorized | Tagged: activity, ADT, androgen, deprivation, function, sex | 5 Comments »
A research group at the University of Otago in New Zealand is continuing to investigate how men treated for prostate cancer deal with sexual dysfunction. We have helped them with this before and will continue to do so. … READ MORE …
Filed under: Living with Prostate Cancer | Tagged: activity, post-treatment, sexual, strategies, survey | 1 Comment »
We finally have some published data — albeit not a lot — on the use of one of the PD-1 inhibitors (pembrolizumab, also known as Keytruda) in the treatment of late-stage prostate cancer. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: activity, efficacy, Keytruda, outcome, pembrolizumab, safety, trial | 5 Comments »
According to a presentation given last week in San Francisco, lutetium-177 (177Lu) prostate-specific membrane antigen (PSMA) radioligand therapy has significant clinical activity in men with metastatic prostate cancer (as opposed to just in men with very late stages of prostate cancer). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: activity, lutetium, lutetium-177, outcome, radioligand | 11 Comments »
In an incidentally timely manner, the May issue of Annals of Oncology carries a systematic review and meta-analysis of data on physical activity and risk for prostate cancer. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Prevention, Risk | Tagged: activity, Diagnosis, exercise, physical, Prevention, progression, risk | 1 Comment »
Yet another study has confirmed the benefits of regular exercise in the prevention or delay of prostate cancer-specific mortality among men with non-metastatic prostate cancer. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: activity, exercise, mortality, rate, risk | 2 Comments »
We are well aware that many patients are interested in the potential of “natural products” as effective and safe forms of treatment for cancer. … READ MORE …
Filed under: Drugs in development | Tagged: activity, anethole, natural, product | 2 Comments »
Readers with a strong interest in the relationships between exercise and risk for cancer recurrence may want to download and read the full text of a recent article by Friedenreich et al. … READ MORE …
Filed under: Living with Prostate Cancer, Management | Tagged: activity, exercise, physical, recurrence, risk | Leave a comment »
Back in 2011 we reported a presentation by Scher et al. indicating that circulating tumor cell counts (CTCs) could probably be used to monitor responses to abiraterone acetate (and perhaps other forms of drug therapy) in the treatment of men with metastatic, castration-resistant prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, activity, cell, circulating, count, CTC, surrogate, tumor | 3 Comments »
A new report issued here in the USA by the American Institute for Cancer Research (AIRC) and globally by the World Cancer Research Fund International is focused on “Diet, Nutrition, Physical Activity and Prostate Cancer“. … READ MORE …
Filed under: Diagnosis, Prevention, Risk | Tagged: activity, diet, nutrition, obesity, Prevention, risk | Leave a comment »
Not so long ago (back in late 2013), Schweizer et al. reported data from a very small trial of an old drug called disulfiram (also known as Antabuse) in the treatment of men with progressive prostate cancer after first-line therapy. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: activity, advanced, Antabuse, disulfiram, progressive, safety | 1 Comment »
Apparently a drug known as olaparib (a so-called poly-ADP ribose polymerase or PARP inhibitor) has shown significant signs of activity against advanced prostate cancer in men who carry the BRCA1 and BRCA2 genes. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: activity, BRCA1, BRCA2, olaparib | 2 Comments »
The idea that exercise and physicial fitness may be associated with a reduction in risk of disease progression in men with relatively low-risk prostate cancer is hardly new, but … READ MORE …
Filed under: Living with Prostate Cancer, Management, Prevention, Uncategorized | Tagged: activity, exercise, low risk, preventiuon, progression | 5 Comments »
Researchers at Columbia University are reporting that a complex mixture of 33 different nutrients, medicinal mushrooms, minerals, and herbs seems to have significant activity affecting the growth and survival of androgen-dependent and androgen-independent prostate cancer cells lines derived from mice and humans. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: activity, nutritional supplement, PectaSol, ProstaCaid | 5 Comments »
Data presented at the annual meeting of the American Society for Cancer Research suggest that a group of drugs called benzimidazoles may have activity in the treatment of advanced prostate cancer — at least in laboratory mice. … READ MORE …
Filed under: Drugs in development, Management | Tagged: activity, benzimidazole, mice | Leave a comment »
THE "NEW" PROSTATE CANCER INFOLINK 